{"_buckets": {"deposit": "084e8ba5-75e7-4d1b-8ea4-85a2cab2e119"}, "_deposit": {"created_by": 2, "id": "2479", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "2479"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00002479", "sets": ["9"]}, "author_link": ["11494", "11491", "11489", "11486", "11487", "11493", "11492", "11490", "11488", "11485"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-06-29", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "3214", "bibliographicPageStart": "3211", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "OncoTargets and Therapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However, the patient’s blood creatinine level increased, and her physical status worsened. Alectinib also induced exacerbation of renal dysfunction but was controlled by dose reduction of 140 mg twice daily for 2 weeks treatment and 2 weeks break were repeated, and exhibited a partial response for 16 months. Here, we describe the case in which alectinib treatment had beneficial clinical effects on ALK-positive lung adenocarcinoma, which controlled the adverse renal effects by dose reduction and drug breaks.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "OncoTargets and Therapy, 10, pp.3211-3214; 2017", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Dove press Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2147/OTT.S136837", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2017 Shimada et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution ? Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "11786930", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shimada, Midori"}], "nameIdentifiers": [{"nameIdentifier": "11485", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "11486", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "11487", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitazaki, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "11488", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashiguchi, Kohji"}], "nameIdentifiers": [{"nameIdentifier": "11489", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "11490", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "11491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "11492", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ashizawa, Kazuto"}], "nameIdentifiers": [{"nameIdentifier": "11493", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "11494", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OTT_10_3211.pdf", "filesize": [{"value": "698.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 698900.0, "url": {"label": "OTT_10_3211.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/2479/files/OTT_10_3211.pdf"}, "version_id": "055cf224-3832-4fd0-b8ca-d6168875efe2"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ALK", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal dysfunction", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alectinib", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/37689", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-07-31"}, "publish_date": "2017-07-31", "publish_status": "0", "recid": "2479", "relation": {}, "relation_version_is_last": true, "title": ["Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction"], "weko_shared_id": -1}